Novo Nordisk Remains Focused on Diabetes Care: Brandgaard

The transcript discusses the company's financial outlook, highlighting a 5% negative impact on U.S. sales due to pricing pressures. It addresses market reactions to changes in long-term financial targets and emphasizes the need for diversification, particularly in emerging markets. The focus remains on diabetes care, with strategic investments planned. The company is cautious about utilizing its strong balance sheet for acquisitions, preferring to maintain its capital structure to support diabetes care initiatives.

What criteria does the speaker mention for aligning their research portfolio?

What is the speaker's stance on utilizing their balance sheet for acquisitions?

What investment level is anticipated in the diabetes care area?